BC Extra | Jan 14, 2020
Financial News

Tyra raises $50M series A for cancer drug resistance

Tyra Biosciences emerged from stealth with a $50 million series A round to bring its first therapy to the clinic for drug-resistant cancer. Alta Partners, RA Capital Management, Boxer Capital of Tavistock Group and Canaan...
BC Week In Review | Feb 9, 2015
Clinical News

Sivextro tedizolid phosphate regulatory update

EMA’s CHMP recommended approval of oral and IV Sivextro tedizolid from Merck to treat acute bacterial skin and skin structure infections (ABSSSI) in adults. CHMP said the authorization would include a pharmacovigilance plan. FDA approved...
BC Extra | Jan 24, 2015
Company News

CHMP recommends Sivextro for ABSSSI

EMA's CHMP recommended marketing authorization of oral and IV Sivextro tedizolid from Merck & Co. Inc. (NYSE:MRK) to treat acute bacterial skin and skin structure infections (ABSSSI) in adults. CHMP said the authorization would include...
BC Week In Review | Dec 15, 2014
Company News

Cubist, Merck deal

Merck will acquire Cubist for $102 per share and $1.1 billion in assumption of debt in a deal valued at $9.5 billion. The cash offer of $102 per share, or $8.4 billion, represents a 37%...
BioCentury | Dec 15, 2014
Finance

Uphill road for Cubist CVRs

When Merck & Co. Inc. (NYSE:MRK) acquires Cubist Pharmaceuticals Inc. (NASDAQ:CBST), the pharma will take over the contingent value rights the infectious disease company owes the former shareholders of Optimer Pharmaceuticals Inc. and Trius Therapeutics...
BC Extra | Dec 9, 2014
Top Story

Cubist: Court ruling won't upend Merck takeout

Shares of Cubist Pharmaceuticals Inc. (NASDAQ:CBST) receded slightly in after-hours trading on Monday after surging $26.24 (35%) to $100.60 on news Merck & Co. Inc. (NYSE:MRK) will acquire the biotech for $9.5 billion, including the...
BC Extra | Oct 7, 2014
Top Story

Actavis raises stakes in ABSSSI race

Actavis plc (NYSE:ACT) will acquire Durata Therapeutics Inc. (NASDAQ:DRTX) for $675 million in cash up front, or $23 per share, plus up to $146.5 million in regulatory and commercial milestones in the form of a...
BC Week In Review | Sep 22, 2014
Company News

Adenium Biotech management update

Adenium Biotech ApS , Copenhagen, Denmark   Business: Infectious   Hired: Edward Fang as CMO, formerly director of clinical sciences at Trius Therapeutics Inc. , which Cubist Pharmaceuticals Inc. acquired  ...
BC Week In Review | Sep 1, 2014
Company News

Cubist sales and marketing update

Cubist launched an IV formulation of Sivextro tedizolid in the U.S. to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). An oral formulation of...
BioCentury | Jul 14, 2014
Finance

Cidara's antimicrobial reunion

Investors in Cidara Therapeutics Inc. 's $32 million series A round are hoping for a repeat performance by a management team with a track record of exits in the infectious disease space. 5AM Ventures led...
Items per page:
1 - 10 of 142
BC Extra | Jan 14, 2020
Financial News

Tyra raises $50M series A for cancer drug resistance

Tyra Biosciences emerged from stealth with a $50 million series A round to bring its first therapy to the clinic for drug-resistant cancer. Alta Partners, RA Capital Management, Boxer Capital of Tavistock Group and Canaan...
BC Week In Review | Feb 9, 2015
Clinical News

Sivextro tedizolid phosphate regulatory update

EMA’s CHMP recommended approval of oral and IV Sivextro tedizolid from Merck to treat acute bacterial skin and skin structure infections (ABSSSI) in adults. CHMP said the authorization would include a pharmacovigilance plan. FDA approved...
BC Extra | Jan 24, 2015
Company News

CHMP recommends Sivextro for ABSSSI

EMA's CHMP recommended marketing authorization of oral and IV Sivextro tedizolid from Merck & Co. Inc. (NYSE:MRK) to treat acute bacterial skin and skin structure infections (ABSSSI) in adults. CHMP said the authorization would include...
BC Week In Review | Dec 15, 2014
Company News

Cubist, Merck deal

Merck will acquire Cubist for $102 per share and $1.1 billion in assumption of debt in a deal valued at $9.5 billion. The cash offer of $102 per share, or $8.4 billion, represents a 37%...
BioCentury | Dec 15, 2014
Finance

Uphill road for Cubist CVRs

When Merck & Co. Inc. (NYSE:MRK) acquires Cubist Pharmaceuticals Inc. (NASDAQ:CBST), the pharma will take over the contingent value rights the infectious disease company owes the former shareholders of Optimer Pharmaceuticals Inc. and Trius Therapeutics...
BC Extra | Dec 9, 2014
Top Story

Cubist: Court ruling won't upend Merck takeout

Shares of Cubist Pharmaceuticals Inc. (NASDAQ:CBST) receded slightly in after-hours trading on Monday after surging $26.24 (35%) to $100.60 on news Merck & Co. Inc. (NYSE:MRK) will acquire the biotech for $9.5 billion, including the...
BC Extra | Oct 7, 2014
Top Story

Actavis raises stakes in ABSSSI race

Actavis plc (NYSE:ACT) will acquire Durata Therapeutics Inc. (NASDAQ:DRTX) for $675 million in cash up front, or $23 per share, plus up to $146.5 million in regulatory and commercial milestones in the form of a...
BC Week In Review | Sep 22, 2014
Company News

Adenium Biotech management update

Adenium Biotech ApS , Copenhagen, Denmark   Business: Infectious   Hired: Edward Fang as CMO, formerly director of clinical sciences at Trius Therapeutics Inc. , which Cubist Pharmaceuticals Inc. acquired  ...
BC Week In Review | Sep 1, 2014
Company News

Cubist sales and marketing update

Cubist launched an IV formulation of Sivextro tedizolid in the U.S. to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). An oral formulation of...
BioCentury | Jul 14, 2014
Finance

Cidara's antimicrobial reunion

Investors in Cidara Therapeutics Inc. 's $32 million series A round are hoping for a repeat performance by a management team with a track record of exits in the infectious disease space. 5AM Ventures led...
Items per page:
1 - 10 of 142